These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 21900189)

  • 21. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic value of (18)F-FDG PET/CT in newly diagnosed multiple myeloma patients].
    Wang CY; Wu L; Sun CT; Wang X; Xia B; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(4):301-306. PubMed ID: 30669718
    [No Abstract]   [Full Text] [Related]  

  • 23. Utility and prognostic value of
    Aljama MA; Sidiqi MH; Buadi FK; Lacy MQ; Gertz MA; Dispenzieri A; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame RM; Kourelis T; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Rajkumar SV; Kumar SK
    Am J Hematol; 2018 Dec; 93(12):1518-1523. PubMed ID: 30194770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limited Prognostic Value of SUV max Measured by F-18 FDG PET/CT in Newly Diagnosed Small Cell Lung Cancer Patients.
    Kim SJ; Chang S
    Oncol Res Treat; 2015; 38(11):577-85. PubMed ID: 26599271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment response evaluation with
    Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
    Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.
    Ulaner GA; Goldman DA; Sauter CS; Migliacci J; Lilienstein J; Gönen M; Schöder H; Moskowitz CH; Zelenetz AD
    Radiology; 2015 Nov; 277(2):518-26. PubMed ID: 26035588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.
    Jiang C; Zhang X; Jiang M; Zou L; Su M; Kosik RO; Tian R
    Ann Nucl Med; 2015 Jun; 29(5):442-51. PubMed ID: 25801633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standardization of
    Zamagni E; Nanni C; Dozza L; Carlier T; Bailly C; Tacchetti P; Versari A; Chauvie S; Gallamini A; Gamberi B; Caillot D; Patriarca F; Macro M; Boccadoro M; Garderet L; Barbato S; Fanti S; Perrot A; Gay F; Sonneveld P; Karlin L; Cavo M; Bodet-Milin C; Moreau P; Kraeber-Bodéré F
    J Clin Oncol; 2021 Jan; 39(2):116-125. PubMed ID: 33151787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.
    Qiao W; Zhao J; Xing Y; Wang C; Wang T
    Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
    Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluorodeoxyglucose-PET/Computed Tomography as a Predictor of Prognosis in Multiple Myeloma.
    Nanni C; Zamagni E
    PET Clin; 2019 Jul; 14(3):383-389. PubMed ID: 31084777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials.
    Jamet B; Morvan L; Nanni C; Michaud AV; Bailly C; Chauvie S; Moreau P; Touzeau C; Zamagni E; Bodet-Milin C; Kraeber-Bodéré F; Mateus D; Carlier T
    Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1005-1015. PubMed ID: 33006656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J;
    Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
    Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL
    Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.
    Zhu D; Ma T; Niu Z; Zheng J; Han A; Zhao S; Yu J
    Lung Cancer; 2011 Sep; 73(3):332-7. PubMed ID: 21292341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.
    Sucak GT; Özkurt ZN; Suyani E; Yaşar DG; Akdemir ÖÜ; Aki Z; Yeğin ZA; Yağci M; Kapucu ÖL
    Ann Hematol; 2011 Nov; 90(11):1329-36. PubMed ID: 21437590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.